Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 16;11:333. doi: 10.1038/s41467-019-14085-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a KDELR3-001 and KDELR3-002 patient expression data. Empirical Bayes moderated t-statistic (unpaired two-tailed test); KDELR3-001, ENST00000216014, P = 0.0202, t = 2.36, d.f. = 102.17; KDELR3-002, ENST00000409006, P = 0.87, t = 0.16, d.f. = 102.17. Boxplots of patient expression data from TCGA-SKCM dataset, depicting the 25th, 50th (median), and 75th percentile, and extreme values of the transcript expression. “Early” stage (stages I/II, N = 62 patients). “Late” stage (stages III/IV, N = 39 patients). n.s., not significant. b Kaplan–Meier estimated survival curves according to KDELR3 expression in early-stage (GSE8401; n = 27, stages I/II) and late-stage (GSE8401; n = 47, stages III/IV) melanomas. Log-rank test. c Association of KDELR3 expression and survival in metastatic melanoma (GSE19234, n = 38; GSE8401, n = 47, stages III/IV); HR = 1.62 (P = 0.028) and HR = 1.49 (P = 0.032) for GSE19234 and GSE8401, respectively. No significant association was found in the primary tumors (GSE8401, n = 27, stages I/II); HR = 0.76 (P = 0.509). Cox regression model was used to test the association.